Pre-stroke use of beta-blockers does not affect ischaemic stroke severity and outcomeDe Raedt, S., Haentjens, P., De Smedt, A., Brouns, R., Uyttenboogaart, M., Luijckx, G. J. & De Keyser, J., Feb-2012, In : European Journal of Neurology. 19, 2, p. 234-240 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Background and purpose: It is unclear whether pre-stroke beta-blockers use may influence stroke outcome. This study evaluates the independent effect of pre-stroke use of beta-blockers on ischaemic stroke severity and 3 months functional outcome.
Methods: Pre-stroke use of beta-blockers was investigated in 1375 ischaemic stroke patients who had been included in two placebo-controlled trials with lubeluzole. Stroke severity was assessed by either the National Institute of Health Stroke Scale (NIHSS) or the European Stroke Scale (ESS). A modified Rankin scale (mRS) score of >3 at 3 months was used as measure for the poor functional outcome.
Results: Two hundred and sixty four patients were on beta-blockers prior to stroke onset, and 105 patients continued treatment after their stroke. Pretreatment with beta-blockers did not influence baseline stroke severity. There was no difference in stroke severity between nonusers and those on either a selective beta(1)-blocker or a nonselective beta-blocker. The likelihood of a poor outcome at 3 months was not influenced by pre-stroke beta-blocker use or beta-blocker use before and continued after stroke onset.
Conclusions: Pre-stroke use of beta-blockers does not appear to influence stroke severity and functional outcome at 3 months.
|Number of pages||7|
|Journal||European Journal of Neurology|
|Publication status||Published - Feb-2012|
- beta-blocker, cerebral infarction, outcome, severity, FOCAL CEREBRAL-ISCHEMIA, PROVIDES NEUROPROTECTION, ACTIVATES ASTROCYTES, BRAIN-INJURY, PROPRANOLOL, TRIAL, HYPERGLYCEMIA, CARVEDILOL, LUBELUZOLE, BLOCKADE